LYNPARZA (olaparib tablets) Patient Assistance Program
Don’t let the high cost of brand PARP inhibitor disrupt your ovarian, breast, prostate, or pancreatic cancer treatment. We help eligible patients access Lynparza (olaparib tablets) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Lynparza (olaparib) is FDA-approved for maintenance treatment of advanced ovarian cancer (BRCA-mutated or platinum-sensitive), first-line maintenance with bevacizumab for HRD-positive advanced ovarian cancer, treatment of germline BRCA-mutated HER2-negative metastatic breast cancer, adjuvant treatment of high-risk early-stage BRCA-mutated HER2-negative breast cancer, treatment of germline BRCA-mutated metastatic pancreatic cancer in maintenance after platinum-based chemo, and treatment of HRR gene-mutated metastatic castration-resistant prostate cancer. PARP inhibitor — exploits synthetic lethality in homologous recombination repair-deficient tumors.
- Without assistance, Lynparza costs commonly run approximately $14,000–$17,000 per month.
- Through AffordMyPrescriptions, qualifying patients can access Lynparza for a flat $69.95 per month.
- Other PARP inhibitors: niraparib (Zejula), rucaparib (Rubraca), talazoparib (Talzenna). Each PARP inhibitor has slightly different indications and toxicity profiles. Indication-specific alternatives: for ovarian cancer maintenance — bevacizumab (Avastin biosimilars now available), platinum-based chemo retreatment; for BRCA-mutated breast cancer — Talzenna (alternative PARP), platinum chemo, sacituzumab govitecan (Trodelvy), trastuzumab deruxtecan (Enhertu — HER2-low); for metastatic CRPC — Xtandi (enzalutamide), Erleada (apalutamide), Nubeqa (darolutamide), Zytiga (abiraterone — generic), Pluvicto (lutetium-177-PSMA-617), and standard chemotherapies; for pancreatic cancer — gemcitabine + nab-paclitaxel (generic gem + Abraxane), FOLFIRINOX (generic chemo backbone). Tumor genetic testing (BRCA1/2, HRR genes) essential for appropriate selection.
What is Lynparza Prescription Assistance Program?
The Lynparza Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Lynparza (used for BRCA-mutated and HRR-deficient ovarian, breast, prostate, and pancreatic cancers) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, oncology coordination, BRCA or HRR mutation documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing advanced cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Lynparza PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your oncologist for required medical documentation (typically including tumor or germline BRCA/HRR testing results, prior treatment history, and indication-specific clinical criteria), follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Lynparza PARP inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Lynparza enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your cancer treatment.
Pharmacy Price Comparison
- Without assistance, Lynparza costs thousands of dollars per month at specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted cancer therapy accessible if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Lynparza advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$16,500/mo | Save substantially |
| CVS Pharmacy | ~$17,000/mo | Save substantially |
| Walmart | ~$14,500/mo | Save substantially |
| Specialty pharmacy | ~$14,000/mo | Save substantially |
| Zejula (alt PARP) | ~$15,000/mo | Alt PARP inhibitor |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Lynparza — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Lynparza Prescription Program?
The Lynparza Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Tumor genetic testing for BRCA or HRR mutations is essential — Lynparza is most effective in HR-deficient tumors.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Lynparza:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
Coupon cards expire and require constant renewal
- Still $14,000–$17,000 per month even with the best discount
- Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95 for the treatment course — never changes
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- Medicare Part D patients accepted
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Lynparza assistance.
- You are a U.S. citizen or legal resident
- You Have A Valid Lynparza Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Lynparza:
Lynparza is an inhibitor of poly(ADP-ribose) polymerase (PARP) — a DNA repair enzyme. Blocks PARP-mediated repair of single-strand DNA breaks. In tumors with deficient homologous recombination repair (BRCA mutations, other HRR gene defects, or HRD-positive tumors), the combined repair failure creates lethal genomic instability — ‘synthetic lethality.’ Effective across multiple cancer types with BRCA or HRR alterations.
How Lynparza Works:
DNA undergoes constant damage and repair through multiple pathways including base excision repair (BER) using PARP, and homologous recombination repair (HRR) using BRCA1, BRCA2, and other proteins. Tumors with BRCA mutations or other HRR deficiencies rely on PARP-mediated repair to survive.
Olaparib inhibits PARP — preventing repair of single-strand DNA breaks, which then become unrepaired double-strand breaks. In BRCA or HRR-deficient tumors, these double-strand breaks cannot be properly repaired by homologous recombination — leading to genomic instability and cell death (synthetic lethality). Effective in maintenance and treatment of multiple cancer types where HR deficiency drives tumor behavior.
Form and Use:
Lynparza 100 mg or 150 mg tablets. Typical dose 300 mg twice daily. Renal and hepatic dose adjustments. Take with or without food. Continue until disease progression or unacceptable toxicity. Hold and consider dose reduction for hematologic and non-hematologic toxicities per labeling. Periodic CBC monitoring required. Avoid strong CYP3A4 inhibitors (azoles, ritonavir) — reduce dose if combination unavoidable; avoid strong CYP3A4 inducers.
Generic Availability:
No generic Lynparza. Other PARP inhibitors (all brand): niraparib (Zejula — ovarian cancer maintenance), rucaparib (Rubraca — ovarian cancer), talazoparib (Talzenna — BRCA-mutated breast cancer, mCRPC with HRR alterations). For ovarian cancer: bevacizumab (Avastin with biosimilars now available — Mvasi, Zirabev), platinum-based chemo, mirvetuximab soravtansine (Elahere — FRα-positive). For BRCA-mutated breast cancer: Talzenna alternative PARP, platinum chemo, sacituzumab govitecan (Trodelvy), trastuzumab deruxtecan (Enhertu — HER2-low), antibody-drug conjugates, CDK4/6 inhibitors (palbociclib generic now, ribociclib, abemaciclib) for HR+ subset. For metastatic CRPC: Xtandi (enzalutamide), Erleada (apalutamide), Nubeqa (darolutamide), Zytiga (abiraterone — generic now), Pluvicto (lutetium-177-PSMA-617), docetaxel/cabazitaxel chemo (generic). For pancreatic cancer: gemcitabine + nab-paclitaxel (gemcitabine generic + Abraxane), FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, leucovorin — generic chemo). Tumor or germline genetic testing (BRCA1/2 sequencing, HRR panel) is essential to identify patients most likely to benefit.
Warnings:
**Boxed warnings: myelodysplastic syndrome / acute myeloid leukemia (MDS/AML — rare but serious, increases with cumulative exposure; monitor CBC, evaluate for cytopenia patterns), pneumonitis (sometimes fatal — evaluate for new respiratory symptoms), venous thromboembolism (PE, DVT — increased in trials).** Other: hematologic toxicity (anemia, neutropenia, thrombocytopenia — most common dose-limiting, monitor CBC at baseline and monthly), nausea, vomiting, diarrhea, fatigue, anorexia, dysgeusia, embryo-fetal toxicity. Drug interactions: strong CYP3A4 inhibitors (azoles, clarithromycin, ritonavir, grapefruit) increase olaparib levels — reduce dose; strong inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) reduce efficacy — avoid.
FAQ (Frequently Asked Questions)
How much does Lynparza cost without insurance?
$14,000–$17,000 per month. Annual cost can exceed $180,000 without assistance. Specialty pharmacy and Patient Assistance Programs are essential for most patients to access this targeted cancer therapy.
Is Lynparza considered chemotherapy?
No — Lynparza is a targeted oral therapy (PARP inhibitor) — not traditional cytotoxic chemotherapy. Different toxicity profile from chemotherapy but does cause hematologic toxicity and rare risk of secondary blood cancers (MDS/AML).
Why is BRCA or HRR testing required before starting Lynparza?
PARP inhibitors exploit the synthetic lethality between PARP inhibition and homologous recombination deficiency. Tumors with BRCA1/2 mutations or other HRR gene defects (the ‘HRD-positive’ phenotype) are most likely to respond. Tumor and/or germline genetic testing is essential to identify patients who will benefit and avoid unnecessary exposure for those unlikely to respond.
What is the difference between Lynparza, Zejula, Rubraca, and Talzenna?
All are PARP inhibitors. Lynparza (olaparib) has the broadest range of FDA-approved indications across ovarian, breast, prostate, and pancreatic cancers. Zejula (niraparib) is FDA-approved for ovarian cancer maintenance regardless of BRCA status (broader patient pool but PARP-class warnings). Rubraca (rucaparib) for ovarian cancer. Talzenna (talazoparib) for BRCA-mutated breast cancer and mCRPC with HRR alterations. Toxicity profiles differ slightly; choice often by indication, prior treatment history, and insurance.
What is the difference between Lynparza for BRCA-mutated breast cancer and bevacizumab (Avastin)?
Different mechanisms. Lynparza is an oral PARP inhibitor targeting HR-deficient cancer cells. Bevacizumab (Avastin) is an IV anti-VEGF monoclonal antibody (with biosimilars now available — Mvasi, Zirabev) that blocks tumor angiogenesis. They have distinct toxicity profiles and are used in different indications — sometimes combined in ovarian cancer maintenance for HRD-positive disease.
How serious are the FDA boxed warnings for Lynparza?
Serious. Increased risk of myelodysplastic syndrome and acute myeloid leukemia (rare but life-threatening blood cancers) with cumulative PARP inhibitor exposure. Pneumonitis (sometimes fatal) and venous thromboembolism risks. CBC monitoring at baseline and monthly is essential. Evaluate new respiratory symptoms promptly. Discuss VTE prophylaxis with your oncologist.
Why are CBC and lab monitoring essential while taking Lynparza?
Hematologic toxicity (anemia, neutropenia, thrombocytopenia) is the most common dose-limiting toxicity. Monthly CBC after baseline assessment guides dose adjustments. Persistent cytopenias warrant evaluation for MDS/AML.
What happens if my Lynparza Patient Assistance Program application is denied?
We help explore Zejula, Rubraca, or Talzenna copay programs (alternative PARP inhibitors), bevacizumab biosimilar copay programs (alternative ovarian cancer maintenance), generic chemotherapy backbones (gemcitabine, platinum-based, FOLFIRINOX), abiraterone generic for mCRPC, Leukemia & Lymphoma Society copay assistance, CancerCare, Ovarian Cancer Research Alliance, Breast Cancer Research Foundation, Pancreatic Cancer Action Network, Patient Access Network, Patient Advocate Foundation, and Medicare Part D Extra Help and state SPAP programs.
Take Control of Your Medication Costs
Targeted PARP inhibitor therapy for BRCA-mutated and HRR-deficient cancers should not be derailed by cost. Genetic testing and proper patient selection are essential. Our Lynparza advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Lynparza through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.